Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CYR61
REST API REST API
Homo sapiens
CYR61 is differentially expressed in 328 experiments: 165 organism parts: lung, bone marrow, ... (163 more);, 257 disease states: normal, glioblastoma, ... (255 more);, 99 cell types 543 cell lines 51 compound treatments and 62 other conditions.
Synonyms GIG1, IGFBP10, CCN1
Orthologs Q3ZC35_BOVIN (Bos taurus)   Cyr61 (Rattus norvegicus)   ENSCING00000006564 (Ciona intestinalis)   ENSCING00000006772 (Ciona intestinalis)   ENSCING00000006549 (Ciona intestinalis)   ENSCING00000005383 (Ciona intestinalis)   Cyr61 (Mus musculus)   CYR61_CHICK (Gallus gallus)   Ccn (Drosophila melanogaster)   cyr61 (Danio rerio)   cyr61 (Xenopus laevis)   CYR61 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term positive regulation of caspase activity, protein binding, cell-cell adhesion, cell proliferation, heparin binding, negative regulation of apoptosis, positive regulation of BMP signaling pathway, extracellular region, positive regulation of apoptosis, insulin-like growth factor binding, positive regulation of protein kinase activity, cell adhesion, positive regulation of transcription from RNA polymerase II promoter, anatomical structure morphogenesis, chemotaxis, regulation of cell growth, integrin binding, extracellular matrix organization, atrial septum morphogenesis, chondroblast differentiation, positive regulation of cell-substrate adhesion, ventricular septum development, regulation of ERK1 and ERK2 cascade, atrioventricular valve morphogenesis, extracellular matrix binding, positive regulation of cell migration, osteoblast differentiation, positive regulation of cell differentiation, apoptosis involved in heart morphogenesis, positive regulation of phospholipase activity, positive regulation of osteoblast proliferation, positive regulation of cartilage development, intussusceptive angiogenesis, positive regulation of osteoblast differentiation, chorio-allantoic fusion, labyrinthine layer blood vessel development, positive regulation of protein phosphorylation, positive regulation of ceramide biosynthetic process, reactive oxygen species metabolic process, wound healing, spreading of cells
InterPro Term Cys_knot_C, VWF_C, Thrombospondin_1_rpt, IGFBP-like, Cys_knot, IGFBP_CNN
UniProt Accession Q6FI18, O00622, B4DI61, F8W9U7
Search EB-eye ENSG00000142871
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-6573, E-GEOD-1577, E-GEOD-7540, E-GEOD-3526, ... (34 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-4717, ... (39 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-20081, E-GEOD-3529, E-GEOD-19639
SW480
1
3
E-MEXP-1014, E-GEOD-2509, E-MTAB-37, E-GEOD-18005
A549
2
E-GEOD-3202, E-GEOD-6013
DU145
2
E-GEOD-17482, E-GEOD-20089
HCC38
2
E-MTAB-37, E-MTAB-62
Jurkat
2
E-MTAB-62, E-GEOD-1880
537 more value(s).


Cell type

studied in E-GEOD-20193, E-MEXP-1121, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, ... (47 experiments)

Factor Value U/D Experiments
stromal cell
1
4
E-GEOD-1460, E-MEXP-1121, E-MEXP-1327, E-MEXP-2034, E-GEOD-10797 ... (5 experiments)
fibroblast
3
E-GEOD-3204, E-GEOD-26672, E-GEOD-3920
CD14+ monocyte
2
E-MEXP-1600, E-AFMX-5
adipocyte
1
2
E-AFMX-5, E-MTAB-25, E-TABM-145
2
1
E-TABM-145
vascular smooth muscle cell
1
E-TABM-130
93 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-TABM-15, E-GEOD-16363, ... (66 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
4
E-MTAB-37, E-MTAB-62, E-GEOD-2514, E-MEXP-231
glioblastoma
1
4
E-GEOD-6014, E-MTAB-62, E-MTAB-37, E-GEOD-4290, E-MEXP-567 ... (5 experiments)
uterine fibroid
3
E-MTAB-62, E-GEOD-7307, E-GEOD-2724
prostate carcinoma
1
3
E-MEXP-2034, E-MTAB-62, E-GEOD-3868, E-GEOD-96
malignant melanoma
2
E-GEOD-3189, E-MTAB-62
mesothelioma
2
E-MTAB-37, E-MTAB-62
251 more value(s).


Compound treatment

studied in E-GEOD-5741, E-TABM-782, E-GEOD-697, E-TABM-868, E-GEOD-2450, ... (31 experiments)

Factor Value U/D Experiments
CNOT7 + non-targeting
1
1
E-MEXP-2218
glutamine
1
E-MEXP-941
water
1
E-MEXP-1372
unknown
1
E-GEOD-7307
TGF
1
E-GEOD-15205
hydrogen peroxide
1
E-GEOD-5339
45 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-TABM-325, E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-2191, E-GEOD-21374, ... (9 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-1614, E-GEOD-20033, E-MEXP-2359, ... (10 experiments)

Disease staging
studied in E-GEOD-19743, E-GEOD-22544, E-GEOD-3325, E-GEOD-2509, E-TABM-147, ... (8 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, ... (8 experiments)

Genotype
studied in E-GEOD-3494, E-GEOD-17476, E-GEOD-21750, E-GEOD-22593, E-GEOD-2724, ... (11 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-2657, E-GEOD-20540, E-GEOD-10315, E-TABM-440, E-MEXP-1273, ... (15 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-1956, E-GEOD-1926, E-TABM-26, ... (32 experiments)

individual id
studied in E-GEOD-19519

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-9723, E-GEOD-6802

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Phenotype
studied in E-GEOD-1493, E-GEOD-21750, E-GEOD-17636

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-17204

RNAi
studied in E-MEXP-2115, E-GEOD-1703, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, ... (11 experiments)

Sample preparation
studied in E-GEOD-16728

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-21164, E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-19069, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Tissue
studied in E-GEOD-30573

Treatment
studied in E-GEOD-16193, E-GEOD-19246, E-GEOD-19815, E-GEOD-15799

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-1561, E-GEOD-4922, E-TABM-147 ... (5 experiments)

Processing time: 0.393 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM